Johnson & Johnson (JNJ), Valeant Pharmaceuticals Intl Inc (VRX): Why The Cooper Companies, Inc. (COO) Earnings Could Look Healthier

But Cooper has also been smart about strategic moves. In May, it announced the sale of its Asahikasei Aime unit to Nippon Contact Lens. The original purchase of the unit in 2010 helped Cooper with sales of its Biofinity contact lenses in Japan, but the unit’s weaker margins led Cooper to seek to sell it off.

One key question for Cooper is whether it could be a takeover target. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)‘ $8.7 billion purchase of Bausch & Lomb heightened awareness of the value of vision-related businesses. With Cooper’s market cap at $6.4 billion, a takeover deal would likely cost about the same amount including an acquisition premium.

In the Cooper earnings report, watch to see how the company’s market share in the contact-lens market is faring, especially with its new one-day offerings. In addition, with the women’s-health unit having posted faster revenue growth in past quarters, you’ll want to pay attention to whether that trend continues to support The Cooper Companies, Inc. (NYSE:COO)’s overall growth rates.

The article Why Cooper Earnings Could Look Healthier originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.